CVS Health Corp
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.30%.
Did CVS Beat Earnings? Q2 2025 Results
CVS Health delivered a strong second-quarter beat, posting adjusted EPS of $1.81 against a consensus estimate of $1.46, a 23.85% positive surprise, while revenue climbed 8.4% year-over-year to $98.92 billion, topping the $94.59 billion Wall Street had expected. The standout driver was a sharp recovery in Health Care Benefits, where Aetna's adjusted operating income jumped 39.4% to $1.31 billion, fueled by favorable individual exchange risk adjustment estimates and improved Government business performance. That momentum more than offset ongoing pressure in Health Services, where pharmacy client price improvements weighed on margins, and absorbed $833.00 million in legacy litigation charges that pushed GAAP EPS down to $0.80. Analysts have noted that CVS's individual plan performance sets it apart from peers navigating similar utilization headwinds. Looking ahead, management raised its full-year 2025 adjusted EPS guidance to $6.30 to $6.40 from $6.00 to $6.20, and lifted operating cash flow guidance to at least $7.50 billion, signaling confidence that the company's turnaround trajectory remains intact.
- Significant and durable recovery at Aetna with adjusted operating income up 39.4%
- Favorable year-over-year impact of changes to individual exchange business risk adjustment estimates
- Improved underlying performance in Government business
- Pharmacy drug mix and increased prescription and front store volume in Pharmacy & Consumer Wellness
- Same store prescription volume increased 6.4% on a 30-day equivalent basis
- Revenue growth across all operating segments
- Improved purchasing economics in Health Services
“What people want most — a connected, simpler health care experience — is what CVS Health uniquely provides. For the 185 million people we serve, we deliver better access, greater affordability and aligned advocacy. Our strong performance demonstrates the continued focus we have on operational and financial improvement across our businesses, led by a significant and durable recovery at Aetna, strong retention at CVS Caremark and growth and momentum at CVS Pharmacy.”
CVS Health CEO, on the earnings call
Forward Guidance & Outlook
CVS Health raised its full-year 2025 adjusted EPS guidance to $6.30–$6.40 (from $6.00–$6.20), reflecting strong Q2 performance in Health Care Benefits and Pharmacy & Consumer Wellness, partially offset by a decrease in Health Services. GAAP diluted EPS guidance was revised down to $3.84–$3.94 (from $4.23–$4.43) due to legacy litigation charges. Cash flow from operations guidance was raised to at least $7.5 billion from approximately $7.0 billion.
CVS YoY Financials
CVS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.